LPCUF News Alert Lees Pharmaceutical (LPCUF) 1.1500 10/01/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Lees Pharmaceutical (LPCUF) 1.1500 $LPCUF

Alopecia Pipeline Review Report H2 2014 - 12 Companies & 19 Drug Profiles
M2 - Mon Sep 08, 10:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wmx88j/alopecia) has announced the addition of the "Alopecia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alopecia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alopecia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Valeant Pharmaceuticals International, Inc. - Taisho Pharmaceutical Co., Ltd. - AntiCancer, Inc. - Panacea Biotec Limited - C3 Jian, Inc - ProCertus BioPharm Inc. - AndroScience Corporation - Hygeia Therapeutics, Inc. - Kuhnil Pharmaceutical Co., Ltd. - Lee's Pharmaceutical Holdings Limited - vida therapeutics inc. Drug Profiles - DHL-HisZnNa - abatacept - CB-0301 - ProDermaCel - calcitriol - ZK-003 - HYG-430 - HYG-420 - HYG-410 - ASCJ-9 - KI-1104 - Peptide for Alopecia - Small Molecule to Inhibit ALK5 for Alopecia and Fibrosis - V-2248 - Peptide for Alopecia and Chemotherapy Effects - Lipo-4MA - KI-1105 - Drug to Activate P2Y5 Receptor for Alopecia - Small Molecules to Inhibit PAI-1 for Thromboembolic Disease, PCOS and Alopecia For more information visit http://www.researchandmarkets.com/research/wmx88j/alopecia

Idiopathic (Essential) Hypertension - Pipeline Review, H1 2014
M2 - Mon Jun 16, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h6fdl5/idiopathic) has announced the addition of the "Idiopathic (Essential) Hypertension - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic (Essential) Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic (Essential) Hypertension and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Idiopathic (Essential) Hypertension - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Idiopathic (Essential) Hypertension pipeline depth and focus of Indication therapeutics Companies Mentioned: - Novartis AG - Actelion Ltd - Forest Laboratories, Inc. - Les Laboratoires Servier SAS - Bayer AG - XOMA Corporation - Ahn-Gook Pharmaceutical Co., Ltd. - PhaseBio Pharmaceuticals, Inc. - Lee's Pharmaceutical Holdings Limited - NanoForm Therapeutics Ltd. For more information visit http://www.researchandmarkets.com/research/h6fdl5/idiopathic




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 74

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 204

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Retirement Dreams Dashed: 61% Withdraw Early

Updated Category News Views 204

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Continue Reading
MV Transportation Celebrates Leadership Nomination for FTA

Updated Category News Views 174

MV Throws Support Behind Aesch for FTA Role In this wild world where public transit feels the heat from financial burdens, MV Transportation's recent move to support Mark Aesch for the Federal Transit Administration's top spot isn’t just a nod of approval—it's a full-blown trumpet blast. They're not just doling out a basic endorsement here; they're practically waving...

Continue Reading
Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Updated Category News Views 234

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

Continue Reading
El Pollo Loco Faces Class Action Over Wage Practices

Updated Category News Views 251

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 170

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 127

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Updated Category News Views 239

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

Continue Reading
PASCAL's Holiday Gift Edit: Timeless Watches Shine

Updated Category News Views 167

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Developments at Metals Exploration's La India Project

Updated Category News Views 256

Promising Outcomes of La India Gold Project Metals Exploration PLC (AIM: MTL), known for its expertise in gold production, has shared encouraging initial estimates from its internal analysis concerning the La India gold project in Nicaragua. These findings highlight a notable advancement when compared to the previous Bankable Feasibility Study (BFS) undertaken by SRK...

Continue Reading
Palo Alto Networks Faces Downgrade Amid CyberArk Acquisition Risk

Updated Category News Views 369

Palo Alto Networks Faces Recent Downgrade Palo Alto Networks, Inc. (NASDAQ: PANW) experienced a significant dip in its stock value, falling over 5% recently. This decline came on the heels of concerns surrounding strategic risks associated with its acquisition of CyberArk Software Ltd. (NASDAQ: CYBR). Concerns Over Acquisition Integration The acquisition has sparked...

Continue Reading
Widescale Protests Erupt in Slovakia Over Gas Supply Politics

Updated Category News Views 193

Protests Against Slovakia's Pivot Towards Russia In recent days, thousands of demonstrators gathered in Bratislava, expressing their discontent with Prime Minister Robert Fico's policies towards Russia amid a gas dispute with Ukraine. The protests highlighted growing concerns over Slovakia's geopolitical alignments and the implications for the country's future in Europe....

Continue Reading
Engage with The Hackett Group's Q4 2024 Earnings Call Details

Updated Category News Views 204

Join The Hackett Group for an Insightful Earnings Call The Hackett Group, Inc. (NASDAQ: HCKT) is excited to announce its upcoming earnings conference call scheduled for February 18, 2025. This call follows the release of its fourth-quarter financial results for the period ending December 27, 2024, which will be made public after the market closes on that day. Conference...

Continue Reading
Tintina Mines Welcomes New Director Amid Leadership Changes

Updated Category News Views 81

Tintina Mines Announces Leadership Changes Tintina Mines Limited (TSXV: TTS) has recently undergone a leadership transition, announcing the resignation of Mr. Ricardo Landeta from his position as Director. His decision to resign is due to personal reasons, marking a significant change for the firm. Introduction of New Director In conjunction with Mr. Landeta's departure,...

Continue Reading